The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

April 16, 2019

Study Completion Date

April 16, 2019

Conditions
Psoriasis
Interventions
DRUG

Humira®

Duration - 58 weeks

DRUG

BI 695501

Duration - 58 weeks

Trial Locations (49)

1001

Riga 1st Hosp, Out-patient Department, Riga

1135

UNO Medical Trials Kft., Budapest

4400

Szabolcs-Szatmar-Bereg Univ.teach.Hosp, Nyíregyháza

5000

ALLERGO-DERM BAKOS Kft., Szolnok

10783

Rothhaar Studien GmbH, Berlin

27262

Dermatology Consulting Services, High Point

29681

Palmetto Clinical Trial Services, LLC, Fountain Inn

32127

Progressive Medical Research, Port Orange

33012

Universal Clinical Research, Hialeah

33175

New Horizon Research Center, Miami

33409

Palm Beach Research Center, West Palm Beach

33612

University of South Florida, Tampa

34471

Renstar Medical Research, Ocala

35205

Total Skin and Beauty Dermatology Center, PC, Birmingham

35233

University of Alabama at Birmingham, Birmingham

48706

Great Lakes Research Group, Inc., Bay City

49008

SI Road Clinical Hospital of DS of SE PZ Dept of Dermatovenerology SI DMA of MOHU, Dnipro

64506

MediSearch Clinical Trials, Saint Joseph

66215

Kansas City Dermatology, PA, Overland Park

69063

CI Zaporizhzhia Regional Dermatovenerologic Clinical Dispensary of Zaporizhzhia RC, Zaporizhzhia

73000

Kherson clin.hosp.Afanasiia&Olhy Tropinykh, Kherson

76011

Arlington Research Center, Arlington

77004

Center for Clinical Studies, Houston

78229

Clinical Trials of Texas, Inc., San Antonio

88000

Treatment - Diagnostic Center PE Asclepius, Uzhhorod

90045

Dermatology Research Associates, Los Angeles

91403

Shahram Jacobs MD, Inc./Unison Clinical Trials, Sherman Oaks

92024

California Dermatology & Clinical Research Institute, Encinitas

98405

MultiCare Institute for Research and Innovation, Tacoma

194356

"LLC Alliance Biomedical - Russian Group", Saint Petersburg

196143

EKO-Bezopasnost, St. Petersburg, Saint Petersburg

198510

"Institution of Healthcare Nikolaevskaya Hospital", Saint Petersburg

02919

Clinical Partners, LLC, Johnston

01069

Klinische Forschung Dresden, GmbH, Dresden

LV-1003

Derma Clinic Riga Ltd, Riga

Health Center 4, Affiliate Diagnostic Center, Riga

J. Kisis Ltd, Riga

LV-3201

Smite Aija practice in dermatology and venerology, Talsi

LV-3601

Outpatient Clinic of Ventspils, Ventspils

80-286

Poradnia Kardiologiczna Jaroslaw Jurowiecki, Gdansk

80-382

Synexus Polska SCM Sp. z o.o. Gdansku, Gdansk, Gdansk

81-384

Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia, Gdynia

31-510

Malopolskie medical center S.C, Krakow, Krakow

90-302

SANTA FAMILIA Centrum Badan, Profilaktyki i Leczenia, Lodz

90-436

Dermoklinika medical center, Lodz, Lodz

32-600

Medicome Sp. z o.o., Oświęcim

96-100

Clinmedica Research Omc sp. z o.o. sp.k., Skierniewice, Skierniewice

70-332

Laser Clin. S.C. Dr T. Kochanowski Dr A. Krolicki, Szczecin, Szczecin

01-192

Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Warsaw

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03210259 - The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis | Biotech Hunter | Biotech Hunter